DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Claims 1-12 are examined in the instant application.
Claim Rejections - 35 USC § 102
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
Claim(s) 1-12 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Takashima et al. (WO 2019/093340, WIPO English Translation attached).
Regarding claims 1-3, Takashima et al. teach a method of producing a pluripotent stem (PS) cell population comprising a set of adherent culture of PS cells in a liquid medium comprising 2-3 μM Go 6983 (a PKCβ inhibitor) and 2 μM XAV939 (a TNKS inhibitor);
and a step of suspension culture of the PS cells after adherent culture (parags. 23-25 and 54-57).
Regarding claim 4, Takashima teaches the liquid medium can comprise transferrin and insulin (parag. 23).
Regarding claim 5, Takashima teaches that the liquid medium can comprise a TGFβ inhibitor (parag. 23).
Regarding claims 6 and 7, Takashima teaches that the liquid medium can comprise Y-27632 (a ROCK inhibitor) (parag. 54).
Regarding claims 8 and 9, Takashima teaches that a cell aggregate is formed during suspension culture and then collected (parags. 25 and 37).
Regarding claim 10, Takashima teaches expressing OCT4, SOX2 and NANOG to obtain iPS cells, thus the pluripotent stem cells would all have an expression of 90% or higher (parag. 11).
Regarding claim 11, Takashima teaches that the cells are iPS cells (parag. 11).
Regarding claim 12, Takashima does not teach that the suspension culture comprises a PKCβ inhibitor and/or TNKS inhibitor (parags. 24 and 25).
Thus the teachings of Takashima clearly anticipate the invention of claims 1-12.
Conclusion
No claims are allowed.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to DAVID A MONTANARI whose telephone number is (571)272-3108. The examiner can normally be reached M-Tr 8-6.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Peter Paras can be reached at 571-272-4517. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/DAVID A MONTANARI/Examiner, Art Unit 1632